AN ASSESSEMENT OF THE COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS MULTIPLE COMPARATORS AS FIRST LINE ANTIDEPRESSANT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD) IN BELGIUM

被引：0

作者：

Druais, S. ^{[1
]}

Gauthier, A. ^{[1
]}

Demyttenaere, K. ^{[2
]}

Brignone, M. ^{[3
]}

De Pauw, A. ^{[4
]}

Defraigne, G. ^{[4
]}

Annemans, L. ^{[5
,6
]}

机构：

[1] Amaris, London, England

[2] Univ Psychiat Ctr KuLeuven, Louvain, Belgium

[3] Lundbeck SAS, Issy Les Moulineaux, France

[4] sa Lundbeck nv, Brussels, Belgium

[5] Univ Ghent, B-9000 Ghent, Belgium

[6] Univ Brussels, Ghent, Belgium

来源：

VALUE IN HEALTH | 2012年 / 15卷 / 07期

关键词：

D O I：

10.1016/j.jval.2012.08.815

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A338 / A338

页数：1

共 50 条

[1] COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS VENLAFAXINE IN SECOND-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN SWEDEN
Despiegel, N.
Danchenko, N.
Maman, K.
VALUE IN HEALTH, 2009, 12 (03) : A177 - A177
[2] A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium
Demyttenaere, K
Hemels, MEA
Hudry, J
Annemans, L
CLINICAL THERAPEUTICS, 2005, 27 (01) : 111 - 124
[3] Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
Mencacci, Claudio
Di Sciascio, Guido
Katz, Pablo
Ripellino, Claudio
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2013, 5 : 87 - 99
[4] Cost-effectiveness of escitalopram versus citalopram in outpatients suffering from major depressive disorder
Fantino, B.
Moore, N.
VALUE IN HEALTH, 2006, 9 (06) : A313 - A313
[5] Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria
Hemels, MEH
Kasper, S
Walter, E
Einarson, TR
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (06) : 869 - 878
[6] Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder
Fantino, Bruno
Moore, Nicholas
Verdoux, Helene
Auray, Jean-Paul
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (02) : 107 - 115
[7] Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany
Kulp, W
Hemels, M
Greiner, W
Graf, VDJ
VALUE IN HEALTH, 2005, 8 (06) : A210 - A210
[8] Cost-effectiveness analysis of escitalopram in the treatment of major depressive disorder in Turkey
Hemels, ME
Karamustafyoglu, O
Ozmen, E
Dilsad, S
Mene, S
VALUE IN HEALTH, 2005, 8 (03) : 392 - 392
[9] A cost-effectiveness analysis of escitalopram and sertraline in the treatment of major depressive disorder
Armstrong, EP
Skrepnek, GH
Malone, DC
Erder, H
VALUE IN HEALTH, 2005, 8 (03) : 393 - 393
[10] Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium
Lieven Annemans
Mélanie Brignone
Sylvain Druais
Ann De Pauw
Aline Gauthier
Koen Demyttenaere
PharmacoEconomics, 2014, 32 : 479 - 493

← 1 2 3 4 5 →